Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen

Infectious Diseases and Therapy

Volumn 5, Issue 1, 2016, Pages 73-79

  Patel, Ursula C ^a   Nicolau, David P ^b   Sabzwari, Rabeeya K ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b HARTFORD HOSPITAL   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bacteremia; Ceftolozane tazobactam; Multi drug resistant; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; CEFTOLOZANE PLUS TAZOBACTAM; CEFTRIAXONE; COLISTIN;

AGED; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE RATIO; ARTICLE; BACTEREMIA; BLOOD CULTURE; BLOODSTREAM INFECTION; CASE REPORT; CHILL; CHRONIC KIDNEY DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DRUG HALF LIFE; FEVER; HUMAN; HYDRONEPHROSIS; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PYELOGRAPHY; URINE CULTURE;

EID: 84977091066     PISSN: 21938229     EISSN: 21936382     Source Type: Journal    
DOI: 10.1007/s40121-016-0104-3     Document Type: Article

References (23)

1. Cubist Pharmaceuticals US Zerbaxa (ceftolozane/tazobactam) package insert. Lexington, MA; 2014.
2. Sutherland CA, Nicolau DP. Susceptibility profile of Ceftolozane/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa from US Hospitals. Clin Ther. 2015;37(7):1564–71.
3. Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination. Pharmacotherapy. 2015;35(7):701–15.
4. US National Institutes of Health. ClinicalTrials.gov. https://www.clinicaltrials.gov/ct2/show/NCT02070757?term=ceftolozane+tazobactam&rank=3. Accessed October 28, 2015.
5. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949–56.
6. Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60(10):1462–71.
7. Sutherland CA, Nicolau DP. Development of an HPLC Method for the determination of ceftolozane/tazobactam in biological and aqueous matrixes. J Chromatogr Sci (in press).
8. Wooley M, Miller B, Krishna G, Hershberger E, Chandorkar G. Impact of renal function on the pharmacokinetics and safety of ceftolozane–tazobactam. Antimicrob Agents Chemother. 2014;58(4):2249–55.
9. Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2014;3(1):32.
10. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother. 2003;47:1681–8.
11. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother. 2004;48:4606–10.
12. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–12.
13. VanScoy BD, Mendes RE, Castanheira M. Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. Antimicrob Agents Chemother. 2014;58(10):6024–31.
14. Traugott KA, Echevarria K, Maxwell P, Green K, Lewis JS 2nd. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum. Pharmacotherapy. 2011;31(6):598–608.
15. McCarthy K. Pseudomonas aeruginosa: evolution of antimicrobial resistance and implications for therapy. Semin Respir Crit Care Med. 2015;36:44–55.
16. Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003;37(6):745–51.
17. Morata L, Cobos-Trigueros N, Martínez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2012;56(9):4833–7.
18. Lodise TP, Patel N, Kwa A, et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother. 2007;51(10):3510–5.
19. Osih RB, McGregor JC, Rich SE, et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2007;51(3):839–44.
20. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy. 2005;25(10):1353–64.
21. Oie S, Sawa A, Kamiya A, Mizuno H. In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 1999;44:689–91.
22. Oie S, Uematsu T, Sawa A, et al. In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2003;52:911–4.
23. Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in US Hospitals (2011–2012). Antimicrob Agents Chemother. 2013;57:6305–10.